

Contents

Profile	<ul style="list-style-type: none">1 From Sumitomo Dainippon Pharma to Sumitomo Pharma3 History of Value Creation and Growth5 Corporate Mission / Corporate Culture7 Main Products9 Financial Highlights11 Non-Financial Highlights13 Table of Contents / Editorial Policy
Value Creation Strategies	<ul style="list-style-type: none">15 Changes in the Environment Surrounding Pharmaceutical Companies16 Opportunities and Risks17 Business Model19 Message from the President25 Financial Policy (Message from the President)27 Information Disclosure Based on the TCFD Recommendations (Responses to Climate Change)29 Feature<ul style="list-style-type: none">Fostering “CHANTO,” the capability to deliver the highest performance33 Sustainability and Materiality39 Mid-term Business Plan
Practice & Performance	<ul style="list-style-type: none">41 Mid-term Business Plan 202242 Basic Policy I Establishment of growth engine57 Basic Policy II Building of flexible and efficient organization69 Environment73 Contribution to Societies
Governance	<ul style="list-style-type: none">79 Corporate Governance97 Board Members and Executive Officers<ul style="list-style-type: none">97 Directors / Audit & Supervisory Board Members99 Executive Officers
Financial & Corporate Information	<ul style="list-style-type: none">101 Ten-Year Summary of Selected Financial Data103 Operating Results and Financial Condition, and Business Risks109 Consolidated Financial Statements113 Value Chain Initiatives115 Basic Knowledge of Pharmaceuticals117 Corporate Profile / Shareholder Data119 External Evaluations

Editorial Policy

Applicable period

This report is based on the results for fiscal 2021 (April 1, 2021 to March 31, 2022). Some of the activities described were conducted in fiscal 2022.

Organizational scope

This report is based on the activities of Sumitomo Pharma Co., Ltd. and its consolidated subsidiaries. Some of the information is based on Sumitomo Pharma.

Reference guidelines

- IFRS, International Integrated Reporting Framework
- Company-Investor Dialogue for Collaborative Value Creation compiled by the Ministry of Economy, Trade and Industry of Japan
- GRI Sustainability Reporting Standards
- ISO26000
- International Financial Reporting Standards (IFRS) (applied from the fiscal year ended March 31, 2018)

Disclaimer regarding forward-looking statements

This Report contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties. Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice. Consolidated subsidiary Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Sumitomo Pharma Group holds roughly 52% of the company's outstanding shares. ORGOVYX® (relugolix) and MYFEMBREE®/RYEQO® (relugolix combination tablet) are products owned by Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant.

➔ **For more information, please visit Myovant's website.**

More information about Myovant

(Note) The information in this report is presented on the IFRS core base unless otherwise specified.

Information Disclosure Media

We disclose a variety of information so that our diverse stakeholders understand our business and initiatives. In addition to the investor relations (IR) and sustainability content on our website, we have posted a movie introducing Sumitomo Pharma and videos that introduce our roots and our thoughts on our business. We also publish a Fact Book (published twice a year) and a Corporate Profile.

Corporate Site



IR Site



Sustainability Site



Video: Sumitomo Pharma introduction



Video: Sumitomo Pharma's challenge



Video: Sumitomo Pharma's roots (Only available in Japanese)



Integrated Report 2022



Fact Book 2022



Corporate Profile



Interim shareholder report (Only available in Japanese)

